[{"address1": "245 Main Street", "address2": "Second Floor", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "617 500 8080", "website": "https://immuneering.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.", "fullTimeEmployees": 66, "companyOfficers": [{"maxAge": 1, "name": "Dr. Benjamin J. Zeskind M.B.A., Ph.D.", "age": 40, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1983, "fiscalYear": 2023, "totalPay": 935085, "exercisedValue": 0, "unexercisedValue": 1146738}, {"maxAge": 1, "name": "Mr. Robert J. Carpenter M.B.A., M.S.", "age": 77, "title": "Co-Founder & Chair Emeritus", "yearBorn": 1946, "fiscalYear": 2023, "totalPay": 75357, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Brett M. Hall Ph.D.", "age": 54, "title": "Chief Scientific Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 905415, "exercisedValue": 0, "unexercisedValue": 1402731}, {"maxAge": 1, "name": "Mr. Harold E. Brakewood", "age": 57, "title": "Chief Business Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 579769, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mallory  Morales CPA", "age": 39, "title": "Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer", "yearBorn": 1984, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Paula  George CPA", "title": "Director of Accounting & Operations and Assistant Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael D. Bookman J.D.", "age": 36, "title": "Chief Legal Officer & Secretary", "yearBorn": 1987, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leah R. Neufeld", "age": 50, "title": "Chief People Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  King Ph.D.", "title": "Head of Discovery & VP", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Praveen  Nair Ph.D.", "title": "Head of Translational Pharmacology & VP", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 7, "governanceEpochDate": 1724803200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.16, "open": 1.15, "dayLow": 1.11, "dayHigh": 1.1598, "regularMarketPreviousClose": 1.16, "regularMarketOpen": 1.15, "regularMarketDayLow": 1.11, "regularMarketDayHigh": 1.1598, "beta": -0.615, "forwardPE": -0.6768293, "volume": 264507, "regularMarketVolume": 264507, "averageVolume": 1568253, "averageVolume10days": 362970, "averageDailyVolume10Day": 362970, "bid": 1.06, "ask": 1.13, "bidSize": 100, "askSize": 300, "marketCap": 32915274, "fiftyTwoWeekLow": 1.0, "fiftyTwoWeekHigh": 9.14, "fiftyDayAverage": 1.1906, "twoHundredDayAverage": 3.6249, "currency": "USD", "enterpriseValue": -22501218, "floatShares": 19115146, "sharesOutstanding": 29653400, "sharesShort": 1983486, "sharesShortPriorMonth": 2875891, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0669, "heldPercentInsiders": 0.29152, "heldPercentInstitutions": 0.32518002, "shortRatio": 0.56, "shortPercentOfFloat": 0.089899994, "bookValue": 2.236, "priceToBook": 0.49642217, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -56066460, "trailingEps": -1.9, "forwardEps": -1.64, "enterpriseToEbitda": 0.374, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "IMRX", "underlyingSymbol": "IMRX", "shortName": "Immuneering Corporation", "longName": "Immuneering Corporation", "firstTradeDateEpochUtc": 1627651800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e5829551-96d1-35fc-9c6d-d258079bf8f6", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.11, "targetHighPrice": 25.0, "targetLowPrice": 1.5, "targetMeanPrice": 11.07, "targetMedianPrice": 12.0, "recommendationMean": 2.1, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 59728456, "totalCashPerShare": 2.014, "ebitda": -60089768, "totalDebt": 4312013, "quickRatio": 8.808, "currentRatio": 9.392, "debtToEquity": 6.503, "returnOnAssets": -0.37421, "returnOnEquity": -0.61812, "freeCashflow": -31606916, "operatingCashflow": -50819168, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-01"}]